Theodore E. Hebert

Array ( [id] => 17080624 [patent_doc_number] => 20210275630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => INACTIVATION OF DNA REPAIR AS AN ANTICANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/094072 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16094072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17650736 [patent_doc_number] => 11353459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Methods of using PD-L1 expression in treatment decisions for cancer therapy [patent_app_type] => utility [patent_app_number] => 16/092998 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 13612 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848243 [patent_doc_number] => 10639382 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Method for treating leukemia [patent_app_type] => utility [patent_app_number] => 15/487050 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 13616 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13077133 [patent_doc_number] => 10058621 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers [patent_app_type] => utility [patent_app_number] => 15/484308 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 24749 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885287 [patent_doc_number] => 10195175 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors [patent_app_type] => utility [patent_app_number] => 15/481090 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 34727 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230577 [patent_doc_number] => 20190127461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => CANCER TREATMENT PHARMACEUTICAL COMPOSITION USING ANTI-MCT5 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/091209 [patent_app_country] => US [patent_app_date] => 2017-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16091209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925320 [patent_doc_number] => 11046782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination [patent_app_type] => utility [patent_app_number] => 16/089498 [patent_app_country] => US [patent_app_date] => 2017-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 27085 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756106 [patent_doc_number] => 20170202973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1' [patent_app_type] => utility [patent_app_number] => 15/473308 [patent_app_country] => US [patent_app_date] => 2017-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21047 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15473308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587724 [patent_doc_number] => 11325980 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Combination therapy using a LIV1-ADC and a chemotherapeutic [patent_app_type] => utility [patent_app_number] => 16/085511 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5607 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977527 [patent_doc_number] => 20170281681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'POOLED NK CELLS FROM UMBILICAL CORD BLOOD ASSOCIATED WITH ANTIBODIES AND THEIR USES FOR THE TREATMENT OF DISEASE' [patent_app_type] => utility [patent_app_number] => 15/458680 [patent_app_country] => US [patent_app_date] => 2017-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 21300 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15458680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936477 [patent_doc_number] => 20170240627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'SINGLE-CHAIN VARIABLE FRAGMENT ANTI-CD133 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/455688 [patent_app_country] => US [patent_app_date] => 2017-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 26301 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15455688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15247039 [patent_doc_number] => 10509037 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Monoclonal antibodies that specifically block biological activity of a tumor antigen [patent_app_type] => utility [patent_app_number] => 15/454412 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 17682 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15454412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14975423 [patent_doc_number] => 10441596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Methods and compositions related to glucocorticoid receptor antagonists and breast cancer [patent_app_type] => utility [patent_app_number] => 15/448827 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 19798 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16861743 [patent_doc_number] => 11020465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Development of dual whole cell-based vaccine against pancreatic cancer [patent_app_type] => utility [patent_app_number] => 16/082184 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 16135 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16082184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15751333 [patent_doc_number] => 10617749 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-04-14 [patent_title] => Composition of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy [patent_app_type] => utility [patent_app_number] => 15/441816 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 102 [patent_no_of_words] => 18672 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15441816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11689656 [patent_doc_number] => 20170165370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER' [patent_app_type] => utility [patent_app_number] => 15/441653 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 62363 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15441653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12125100 [patent_doc_number] => 20180008686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'AUTOLOGOUS TUMOR VACCINES AND METHODS' [patent_app_type] => utility [patent_app_number] => 15/439201 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10504 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15439201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746847 [patent_doc_number] => 20190256597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => IMMUNOTHERAPY COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/077939 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16077939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569956 [patent_doc_number] => 11318210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Endosialin-binding antibody [patent_app_type] => utility [patent_app_number] => 16/075849 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 16 [patent_no_of_words] => 10920 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11980883 [patent_doc_number] => 20170285037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAME' [patent_app_type] => utility [patent_app_number] => 15/422350 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11934 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422350 [rel_patent_id] =>[rel_patent_doc_number] =>)